Risk and impact of tuberculosis in patients with chronic myeloid leukemia: A nationwide population-based study in Taiwan

International Journal of Cancer

Volumn 136, Issue 8, 2015, Pages 1881-1887

  Liu, Chia Jen ^a,b   Hong, Ying Chung ^b,c   Teng, Chung Jen ^b,d   Hung, Man Hsin ^a,b   Hu, Yu Wen ^a,b   Ku, Fan Chen ^e   Chen, Yung Tai ^a,f   Chien, Sheng Hsuan ^b   Yeh, Chiu Mei ^a   Chen, Tzeng Ji ^a,b   Chiou, Tzeon Jye ^a,b   Gau, Jyh Pyng ^a,b   Tzeng, Cheng Hwai ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^f TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

BCR ABL tyrosine kinase inhibitors; Chronic myeloid leukemia; Extrapulmonary tuberculosis; Hematopoietic stem cell transplantation; Imatinib; Pulmonary tuberculosis

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH IMPACT ASSESSMENT; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; TAIWAN; TREATMENT RESPONSE; TUBERCULOSIS; COMPLICATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; RETROSPECTIVE STUDY; RISK;

ADULT; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; TAIWAN; TUBERCULOSIS;

EID: 84922598887     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29201     Document Type: Article

References (40)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
2. Chang CS, Yang YH, Hsu CN, et al. Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis. BMC Health Services Res 2012;12:359.
3. Feng JY, Su WJ, Chiu YC, et al. Initial presentations predict mortality in pulmonary tuberculosis patients-a prospective observational study. PLoS One 2011;6:e23715.
4. Yu MC, Wu MH, Jou R. Extensively drugresistant tuberculosis, Taiwan. Emerg Infect Dis 2008;14:849-50.
5. Dietz AB, Souan L, Knutson GJ, et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004;104:1094-9.
6. Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004;18:1332-9.
7. Daniels JM, Vonk-Noordegraaf A, Janssen JJ, et al. Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J 2009;33:670-2.
8. Sora F, De Matteis S, Di Mario A, et al. Antituberculosis therapy and imatinib for chronic myeloid leukemia. Clin Infect Dis 2006;43:1224.
9. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53:102-6.
10. Agaimy A, Brueckl V, Schmidt D, et al. Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor. Case Rep Oncol 2013;6:134-42.
11. Shohet SB, Blum SF. Coincident basophilic chronic myelogenous leukemia and pulmonary tuberculosis associated with extreme elevations of blood histamine levels and maturity onset asthma. Cancer 1968;22:173-4.
12. Ghadyalpati N, Prabhash K, Menon H, et al. Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. J Clin Oncol 2010;28:6594.
13. WHO. Definitions and reporting framework for tuberculosis. 2013 Available at: http://apps.who. int/iris/bitstream/10665/79199/1/9789241505345-eng.pdf.
14. Breslow NE, Lubinb JH, Marekc P, et al. Multiplicative models and cohort analysis. J Am Stat Assoc 1983;78:1-12.
15. Harrell FE, Jr, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA 1982;247:2543-6.
16. Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119:2764-7.
17. Kim DW, Banavali SD, Bunworasate U, et al. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res 2010;34:1459-71.
18. Stead WW, Lofgren JP. Does the risk of tuberculosis increase in old age? J Infect Dis 1983;147:951-5.
19. Allotey P, Gyapong M. Gender in tuberculosis research. Int J Tuberc Lung Dis 2008;12:831-6.
20. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009;9:737-46.
21. Lee CH, Lee MC, Shu CC, et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis 2013;13:194.
22. Hu HY, Wu CY, Huang N, et al. Increased risk of tuberculosis in patients with end-stage renal disease: a population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. Epidemiol Infect 2014;142:1-9.
23. Cho YJ, Lee SM, Yoo CG, et al. Clinical characteristics of tuberculosis in patients with liver cirrhosis. Respirology 2007;12:401-5.
24. Ku SC, Tang JL, Hsueh PR, et al. Pulmonary tuberculosis in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27:1293-7.
25. George B, Mathews V, Srivastava V, et al. Tuberculosis among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant 2001;27:973-5.
26. Arslan O, Gurman G, Dilek I, et al. Incidence of tuberculosis after bone marrow transplantation in a single center from Turkey. Haematologia (Budap) 1998;29:59-62.
27. Hughes WT. Mycobacterial infections in bone marrow transplant recipients. Biol Blood Marrow Transplant 2000;6:359-60.
28. Erdstein AA, Daas P, Bradstock KF, et al. Tuberculosis in allogeneic stem cell transplant recipients: still a problem in the 21st century. Transpl Infect Dis 2004;6:142-6.
29. Senn L, Kovacsovics T, Tarr PE, et al. Peritoneal tuberculosis after imatinib therapy. Arch Intern Med 2009;169:312-3.
30. Takashima M, Igaki N, Matsuda T, et al. Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate. Intern Med 2005;44:114-9.
31. Salunke P, Gupta K, Singla N, et al. Meningeal tuberculoma mimicking chloroma in a patient with chronic myeloid leukemia on imatinib. Neurol India 2011;59:628-30.
32. Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105:2473-9.
33. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008;111:1366-77.
34. Steegmann JL, Moreno G, Alaez C, et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003;88:762-8.
35. Santachiara R, Maffei R, Martinelli S, et al. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica 2008;93:1252-5.
36. Breccia M, Girmenia C, Latagliata R, et al. Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. Mediterr J Hematol Infect Dis 2011;3:e2011021.
37. Napier RJ, Rafi W, Cheruvu M, et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell HostMicrobe 2011;10:475-85.
38. Farah R, Awad J. The association of interferon with the development of pulmonary tuberculosis. Int J Clin Pharmacol Ther 2007;45:598-600.
39. Telesca C, Angelico M, Piccolo P, et al. Interferonalpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J Infect 2007;54:e223-6.
40. Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998;157:679-91.